`
` 2
`
` 3
`
` 4
`
` 5
`
` 6
`
` 7
`
` 8
`
` 9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`KARL CSAKY, MD, PhD - DIRECT
`
` 318
`
`macular edema, and diabetic retinopathy.
`
`Q.
`
`For the next bit of your testimony, I want to ask you
`
`just to focus on the AMD indication. Okay?
`
`A.
`
`Q.
`
`Uh-huh.
`
`So let's take down PTX 3097 and go back -- actually,
`
`before we do that let me ask this.
`
`Can we check off the box in Claim 6 for the first
`
`limitation that Mylan or Biocon recommends the first step of
`
`Claim 6?
`
`A.
`
`Q.
`
`Yes, that would be correct.
`
`Let's take down PTX 3097, and then let's keep moving.
`
`What's the next limitation of Claim 6 that you
`
`analyzed to determine whether Mylan's label or Biocon's label
`
`recommends infringement?
`
`A.
`
`So the next limitation is that the treatment, the
`
`method, comprises sequentially administering to the patient by
`
`intravitreal injection a single initial dose of 2 milligrams of
`
`aflibercept.
`
`Q.
`
`Dr. Csaky, does the proposed Yesafili labeling
`
`encourage, recommend, or promote doctors to sequentially
`
`administer to the patient by intravitreal injection a single
`
`initial dose of 2 milligrams of aflibercept?
`
`A.
`
`Q.
`
`Yes.
`
`Let's bring back up the label. That's PTX 3097, and
`
`we're looking at page 1 and the "Dosage and Administration"
`
`C i n d y L . K n e c h t , R M R / C R R / C B C / C C P
`
`P O B o x 3 2 6 W h e e l i n g , W V 2 6 0 0 3 3 0 4 . 2 3 4 . 3 9 6 8
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2003 Page 309
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`
`
` 1
`
` 2
`
` 3
`
` 4
`
` 5
`
` 6
`
` 7
`
` 8
`
` 9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`KARL CSAKY, MD, PhD - DIRECT
`
` 319
`
`section for AMD. Excuse me. We're looking at page 2, and
`
`that's the "Dosage and Administration" section for AMD.
`
`Where does Mylan or Biocon's label recommend that
`
`doctors sequentially administer to the patient by intravitreal
`
`injection a single initial dose of 2 milligrams of aflibercept?
`
`A.
`
`Right. So under the, again, "Dosage and
`
`Administration," it says the recommended dose for Yesafili,
`
`2 milligrams, to be administered intravitreal injection every
`
`four weeks, monthly.
`
`Q.
`
`Okay. And you said every four weeks, monthly. Are
`
`any of those monthly doses a single initial dose?
`
`A.
`
`Q.
`
`A.
`
`Yes.
`
`Which one?
`
`Well, it's the first -- first one would be the
`
`initial dose.
`
`Q.
`
`Fair enough.
`
`We're going to move to the next requirement of
`
`Claim 6 here in just a second, but before we do I want to talk
`
`about a few issues that I think we're going to see over and
`
`over again, and I want to see if we can clear the air on those
`
`first to streamline things.
`
`The patent claims on the right, they refer to
`
`administering aflibercept. Do you see that?
`
`A.
`
`Q.
`
`Yes.
`
`Yesafili's label on the left -- that's PTX 3097 --
`
`C i n d y L . K n e c h t , R M R / C R R / C B C / C C P
`
`P O B o x 3 2 6 W h e e l i n g , W V 2 6 0 0 3 3 0 4 . 2 3 4 . 3 9 6 8
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2003 Page 310
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`
`
` 1
`
` 2
`
` 3
`
` 4
`
` 5
`
` 6
`
` 7
`
` 8
`
` 9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`KARL CSAKY, MD, PhD - DIRECT
`
` 320
`
`refers to administering Yesafili. Do you see that?
`
`A.
`
`Q.
`
`A.
`
`Q.
`
`Yes.
`
`What is the active ingredient in Yesafili?
`
`Aflibercept.
`
`So whenever PTX 3097 recommends administration of
`
`Yesafili, is it recommending the use of aflibercept?
`
`A.
`
`Q.
`
`Yes.
`
`The patent claims also all require that the doses of
`
`aflibercept be 2 milligram doses.
`
`Do you see that?
`
`Yes.
`
`And that will appear in the other claims we look at,
`
`Yes.
`
`Turning back to the "Dosage and Administration"
`
`A.
`
`Q.
`
`right?
`
`A.
`
`Q.
`
`section we looked at earlier -- that's again PTX 3097, page
`
`2 -- what dose of aflibercept does Yesafili's label recommend
`
`that doctors administer?
`
`A.
`
`Q.
`
`2 milligrams.
`
`I know we're only looking at AMD on the screen right
`
`now, but have you reviewed PTX 3097 -- that's the proposed
`
`labeling -- in full?
`
`A.
`
`Q.
`
`Yes.
`
`Is there any dose referred to in PTX 3097 that is not
`
`a 2-milligram dose?
`
`C i n d y L . K n e c h t , R M R / C R R / C B C / C C P
`
`P O B o x 3 2 6 W h e e l i n g , W V 2 6 0 0 3 3 0 4 . 2 3 4 . 3 9 6 8
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2003 Page 311
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`
`
` 1
`
` 2
`
` 3
`
` 4
`
` 5
`
` 6
`
` 7
`
` 8
`
` 9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`KARL CSAKY, MD, PhD - DIRECT
`
` 321
`
`A.
`
`Q.
`
`Not that I could find.
`
`Okay. So whenever PTX 3097 recommends administration
`
`of Yesafili, is it recommending the use of 2 milligrams of
`
`aflibercept?
`
`A.
`
`Q.
`
`Yes.
`
`All right. Last but not least, the claims are all
`
`going to require intravitreal administration, I think an image
`
`that is now burned into our brains.
`
`How does Mylan or Biocon recommend administering
`
`aflibercept in PTX 3097?
`
`A.
`
`Q.
`
`Through intravitreal injection.
`
`Again, any kind of administration other than
`
`intravitreal administration that's described at all in this
`
`label?
`
`A.
`
`Q.
`
`Not that I could find.
`
`For shorthand, whenever PTX 3097 recommends
`
`administering Yesafili, is it, in fact, recommending that
`
`doctors administer a 2-milligram intravitreal dose of
`
`aflibercept?
`
`A.
`
`Q.
`
`Yes.
`
`All right. Then let's keep cruising here. You can
`
`take down PTX 3097 for a moment and turn back to your slides.
`
`Can we check off this box that Yesafili's label
`
`recommends sequentially administering to the patient by
`
`intravitreal injection a single initial dose of 2 milligrams of
`
`C i n d y L . K n e c h t , R M R / C R R / C B C / C C P
`
`P O B o x 3 2 6 W h e e l i n g , W V 2 6 0 0 3 3 0 4 . 2 3 4 . 3 9 6 8
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2003 Page 312
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`
`
` 1
`
` 2
`
` 3
`
` 4
`
` 5
`
` 6
`
` 7
`
` 8
`
` 9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`KARL CSAKY, MD, PhD - DIRECT
`
` 322
`
`aflibercept?
`
`A.
`
`Q.
`
`Yes.
`
`All right. Then let's turn to the next set of
`
`limitations, and I see you've highlighted two.
`
`What are the next limitations of Claim 6 that you'll
`
`address?
`
`A.
`
`So the next limitations are these idea of secondary
`
`doses. And the claims are that there should be one or more
`
`secondary doses of 2 milligrams of aflibercept and that each of
`
`these secondary doses be administered approximately four weeks
`
`following the immediate preceding dose.
`
`Q.
`
`Let's bring back up PTX 3097, still looking at
`
`page 2.
`
`Does Mylan or Biocon's labels recommend that doctors
`
`administer -- excuse me -- does Mylan or Biocon's label
`
`recommend that doctors follow the initial dose with one or more
`
`secondary doses of 2 milligrams of aflibercept wherein each
`
`secondary dose is administered approximately four weeks
`
`following the immediately preceding dose?
`
`A.
`
`Q.
`
`A.
`
`Yes.
`
`Where?
`
`So, again, it says under "Dosage and Administration,"
`
`the recommended dose of Yesafili is 2 milligrams to be
`
`administered every four weeks for the first 12 weeks or three
`
`months.
`
`C i n d y L . K n e c h t , R M R / C R R / C B C / C C P
`
`P O B o x 3 2 6 W h e e l i n g , W V 2 6 0 0 3 3 0 4 . 2 3 4 . 3 9 6 8
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2003 Page 313
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`
`
` 1
`
` 2
`
` 3
`
` 4
`
` 5
`
` 6
`
` 7
`
` 8
`
` 9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`KARL CSAKY, MD, PhD - DIRECT
`
` 323
`
`Q.
`
`And of those first three injections, which, if any,
`
`of those correspond to the secondary doses of the claim
`
`language?
`
`A.
`
`So the secondary doses in this case would be the
`
`second and third injections.
`
`Q.
`
`A.
`
`Q.
`
`Those are the ones after the initial one?
`
`Correct.
`
`Does PTX 3097 recommend that doctors administer those
`
`secondary doses approximately four weeks following the
`
`immediately preceding dose?
`
`A.
`
`Q.
`
`A.
`
`Yes.
`
`Where does it do that?
`
`It says right here that these injections should be
`
`administered every four weeks, approximately every 28 days or
`
`monthly.
`
`Q.
`
`So then let's turn back to your slides. We're
`
`looking at PDX 4028.
`
`Dr. Csaky, can we check off these boxes? Does the
`
`label recommend -- excuse me -- does PTX 3097 recommend both of
`
`these steps of the method of Claim 6?
`
`A.
`
`Q.
`
`Yes.
`
`All right. What's next? What's the next limitation
`
`of Claim 6 you analyzed?
`
`A.
`
`So the next are the "followed by one or more tertiary
`
`doses of 2 milligrams of aflibercept," and this too has another
`
`C i n d y L . K n e c h t , R M R / C R R / C B C / C C P
`
`P O B o x 3 2 6 W h e e l i n g , W V 2 6 0 0 3 3 0 4 . 2 3 4 . 3 9 6 8
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2003 Page 314
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`
`
` 1
`
` 2
`
` 3
`
` 4
`
` 5
`
` 6
`
` 7
`
` 8
`
` 9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`KARL CSAKY, MD, PhD - DIRECT
`
` 324
`
`limitation in that each tertiary dose be administered
`
`approximately eight weeks following the immediate preceding
`
`dose.
`
`Q.
`
`Okay. After recommending the initial and secondary
`
`doses we just looked at, does PTX 3097 encourage, recommend, or
`
`promote that doctors administer one or more tertiary doses of
`
`2 milligrams aflibercept wherein each tertiary dose is
`
`administered approximately eight weeks following the
`
`immediately preceding dose?
`
`A.
`
`Q.
`
`Yes.
`
`Let's pull back up the label. That's PTX 3097.
`
`Dr. Csaky, where is that recommendation?
`
`A.
`
`So, again, it states here under "Dosage and
`
`Administration" that, after the initial doses, they should be
`
`followed by 2 milligrams of the intravitreal injection once
`
`every eight weeks or two months.
`
`Q.
`
`And just in the language of the claims, which of
`
`those 2-milligram intravitreal injections once every eight
`
`weeks or two months are the tertiary doses of the claim?
`
`A.
`
`Q.
`
`A.
`
`All of them.
`
`Any of them that are administered?
`
`Any of them that are administered would be considered
`
`tertiary doses.
`
`Q.
`
`And, again, does the label explicitly recommend
`
`administering tertiary doses once every eight weeks?
`
`C i n d y L . K n e c h t , R M R / C R R / C B C / C C P
`
`P O B o x 3 2 6 W h e e l i n g , W V 2 6 0 0 3 3 0 4 . 2 3 4 . 3 9 6 8
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2003 Page 315
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`
`
` 1
`
` 2
`
` 3
`
` 4
`
` 5
`
` 6
`
` 7
`
` 8
`
` 9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`KARL CSAKY, MD, PhD - DIRECT
`
` 325
`
`A.
`
`Q.
`
`A.
`
`Yes.
`
`Where is that?
`
`Again, it says to be -- injection once every eight
`
`weeks under the dosage and administration label.
`
`Q.
`
`All right. So turning to Slide 29, that's PDX 429,
`
`can we check off these boxes? Does Mylan/Biocon's label
`
`recommend that doctors perform the tertiary dose steps of
`
`Claim 6?
`
`A.
`
`Q.
`
`Yes.
`
`All right. Looking at PDX 430, we've now made it to
`
`the crossed-out limitation. Can we skip this one for purposes
`
`of your analysis?
`
`A.
`
`Q.
`
`Yes, I did.
`
`Then let's turn to Slide PDX 431. What's the last
`
`limitation of Claim 6, Dr. Csaky?
`
`A.
`
`It says, "wherein the aflibercept is formulated as an
`
`isotonic solution."
`
`Q.
`
`Dr. Csaky, did you evaluate whether the Yesafili
`
`aflibercept that Mylan's label recommends doctors administer is
`
`formulated as an isotonic solution?
`
`A.
`
`Q.
`
`A.
`
`Q.
`
`A.
`
`I did not.
`
`Why not?
`
`I'm not a formulation expert.
`
`Do you know if anyone did address that limitation?
`
`I've been informed that Dr. Trout performed that
`
`C i n d y L . K n e c h t , R M R / C R R / C B C / C C P
`
`P O B o x 3 2 6 W h e e l i n g , W V 2 6 0 0 3 3 0 4 . 2 3 4 . 3 9 6 8
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2003 Page 316
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`
`
` 1
`
` 2
`
` 3
`
` 4
`
` 5
`
` 6
`
` 7
`
` 8
`
` 9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`KARL CSAKY, MD, PhD - DIRECT
`
` 326
`
`analysis.
`
`Q.
`
`And just to set expectations, Dr. Trout will testify
`
`as to infringement shortly. I expect him to address that
`
`limitation. And so with that in mind, Dr. Csaky, let's turn to
`
`the next slide, PDX 432. And I just want to ask you, for the
`
`rest of your testimony about Claim 6, I need you to assume that
`
`Dr. Trout will testify that the aflibercept recommended by
`
`Mylan Biocon's label to be administered is formulated in an
`
`isotonic solution.
`
`Do you understand that?
`
`A.
`
`Yes.
`
`THE COURT: While those boxes are checked, Counsel,
`
`would it be a good time to take our morning break?
`
`MS. KAYALI: Absolutely, Your Honor.
`
`THE COURT: We'll do that, then. We'll take
`
`15 minutes. If everybody could be ready to resume at ten after
`
`11:00, we'll resume the doctor's testimony.
`
`Sir, you can take a break if you'd like, and you can
`
`step down. I'll give you the same speech. I recognize you're
`
`an expert; but for purity of our circumstances, yes, the same
`
`speech you heard me give Dr. Yancopoulos yesterday applies to
`
`you. You're a man without a country. No one's being rude or
`
`discourteous, but they're not allowed to talk you midstream.
`
`So we'll go with that.
`
`Otherwise, we'll see everyone here in 15 minutes.
`
`C i n d y L . K n e c h t , R M R / C R R / C B C / C C P
`
`P O B o x 3 2 6 W h e e l i n g , W V 2 6 0 0 3 3 0 4 . 2 3 4 . 3 9 6 8
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2003 Page 317
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`
`
` 1
`
` 2
`
` 3
`
` 4
`
` 5
`
` 6
`
` 7
`
` 8
`
` 9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`KARL CSAKY, MD, PhD - DIRECT
`
` 327
`
`Thank you all.
`
`(A recess was taken from 10:59 a.m. to
`
`11:15 a.m.)
`
`THE COURT: Counsel, you may proceed.
`
`MS. KAYALI: Thank you, Your Honor.
`
`BY MS. KAYALI:
`
`Q.
`
`Dr. Csaky, we're going to hop right back to Slide 32
`
`where we left off. But before I ask the next question there,
`
`earlier in your testimony, I believe you testified that about
`
`1 million patients suffer from AMD. Is that about 1 million in
`
`the United States?
`
`A.
`
`Q.
`
`Correct.
`
`And DME and DR, you also explained that those
`
`diseases are common. Are they common in the United States?
`
`A.
`
`Q.
`
`Correct.
`
`So then let's turn back to where we left off. We had
`
`just checked off all the boxes. Let me just ask this: Is
`
`there anything else in Claim 6 we need to look for in Mylan's
`
`label?
`
`A.
`
`Q.
`
`A.
`
`Q.
`
`No.
`
`We got them all. That's all the limitations?
`
`Correct.
`
`All right. So then let's go to the next slide. And
`
`I want to turn back to the question we started with. That's
`
`PDX 433.
`
`C i n d y L . K n e c h t , R M R / C R R / C B C / C C P
`
`P O B o x 3 2 6 W h e e l i n g , W V 2 6 0 0 3 3 0 4 . 2 3 4 . 3 9 6 8
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2003 Page 318
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`
`
` 1
`
` 2
`
` 3
`
` 4
`
` 5
`
` 6
`
` 7
`
` 8
`
` 9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`KARL CSAKY, MD, PhD - DIRECT
`
` 328
`
`In view of your testimony, in your opinion, does the
`
`Mylan Biocon label, PTX 3097, recommend that doctors perform
`
`every step of the method of Claim 6 to treat AMD using
`
`Yesafili?
`
`A.
`
`Q.
`
`Yes.
`
`Okay. In view of that, does the Mylan Biocon label
`
`recommend that doctors perform a method that infringes Claim 6?
`
`A.
`
`Q.
`
`Yes.
`
`Let's turn to the next slide, then, and ask -- let's
`
`focus now on Question Number 2. Okay?
`
`And, actually, I should back myself up.
`
`Before we focus on Question Number 2, I want to see
`
`if we can do something to help us move just a little faster
`
`through the rest of this examination. We've been looking at
`
`page 2 of PTX 3097.
`
`If we could bring that back up, please. And if we
`
`could call out the -- there you go, Section 2.2, the dosing
`
`instructions for AMD.
`
`Is there anywhere else other than this section on
`
`page 2, "Dosage and Administration," that communicates the same
`
`information about Mylan or Biocon's label recommends that
`
`doctors use Yesafili to treat AMD?
`
`A.
`
`Q.
`
`Not that I can see.
`
`Let's take a look at page 1 of the label. And
`
`page 1, are they what's called the "Highlights of the
`
`C i n d y L . K n e c h t , R M R / C R R / C B C / C C P
`
`P O B o x 3 2 6 W h e e l i n g , W V 2 6 0 0 3 3 0 4 . 2 3 4 . 3 9 6 8
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2003 Page 319
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`
`
` 1
`
` 2
`
` 3
`
` 4
`
` 5
`
` 6
`
` 7
`
` 8
`
` 9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`KARL CSAKY, MD, PhD - DIRECT
`
` 329
`
`Prescribing Information"?
`
`A.
`
`Q.
`
`Yes.
`
`Okay. Do the highlights of the prescribing
`
`information say the same thing about how doctors should
`
`administer Yesafili to treat AMD as the more -- the longer
`
`section on page 2 of the exhibit?
`
`A.
`
`Q.
`
`When I read these, they are identical.
`
`Okay. So, really, what I'm asking is, to avoid
`
`flipping back and forth, can we stick with the highlights of
`
`the prescribing information as we move forward?
`
`A.
`
`Q.
`
`later?
`
`A.
`
`Q.
`
`That would be fine.
`
`It says the same thing as the more detailed stuff
`
`Yes.
`
`All right. Now, let me ask while we have this up, I
`
`see three bullet points under -- on the left. This is
`
`PTX 3097, page 1, the dosage and administration section and the
`
`highlights of the prescribing information. I see three bullet
`
`points that look like they correspond to the three sentences in
`
`the full Section 2.2 dosage and administration on page 2.
`
`Do you see that?
`
`Yes.
`
`Which of those bullet points have you focused your
`
`A.
`
`Q.
`
`testimony on today?
`
`A.
`
`The first bullet point.
`
`C i n d y L . K n e c h t , R M R / C R R / C B C / C C P
`
`P O B o x 3 2 6 W h e e l i n g , W V 2 6 0 0 3 3 0 4 . 2 3 4 . 3 9 6 8
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2003 Page 320
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`
`
` 1
`
` 2
`
` 3
`
` 4
`
` 5
`
` 6
`
` 7
`
` 8
`
` 9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`KARL CSAKY, MD, PhD - DIRECT
`
` 330
`
`Q.
`
`A.
`
`Why did you do that?
`
`I did that because that's the only place in reviewing
`
`this document that I could see that the term "recommended" was
`
`used.
`
`Q.
`
`So how many recommended dosing regimens are there in
`
`Mylan or Biocon's label as to how doctors should administer
`
`Yesafili in order to treat AMD?
`
`A.
`
`Q.
`
`A.
`
`Q.
`
`There's only one recommended way.
`
`Is that the one you've offered testimony on today?
`
`That's the one I've offered testimony on.
`
`Now, let's look at this briefly, because we're going
`
`to get there, for diabetic macular edema and diabetic
`
`retinopathy too.
`
`Are there also highlights of the prescribing
`
`information for diabetic macular edema and diabetic
`
`retinopathy?
`
`A.
`
`Q.
`
`On here all I'm seeing is neovascular wet AMD.
`
`Okay. If we go back to page 1 of PTX 3097, could we
`
`pull up the highlights of the prescribing information at the
`
`bottom for diabetic macular edema and diabetic retinopathy?
`
`Will we also be referring to the highlights of
`
`prescribing information -- let me ask a better question.
`
`Do the highlights of the prescribing information also
`
`instruct doctors about how to use Yesafili to treat DME and DR?
`
`A.
`
`Yes.
`
`C i n d y L . K n e c h t , R M R / C R R / C B C / C C P
`
`P O B o x 3 2 6 W h e e l i n g , W V 2 6 0 0 3 3 0 4 . 2 3 4 . 3 9 6 8
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2003 Page 321
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`
`
` 1
`
` 2
`
` 3
`
` 4
`
` 5
`
` 6
`
` 7
`
` 8
`
` 9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`KARL CSAKY, MD, PhD - DIRECT
`
` 331
`
`Q.
`
`And we're going to come back to that in a minute. I
`
`just wanted to sort of establish where we're headed next.
`
`Let's go back. Let's go back to PDX 4/34 and turn
`
`back to Question Number 2. We're in a world where you just
`
`answered yes to Question Number 1, and now we're asking
`
`ourselves -- you're asking yourself -- will any doctor perform
`
`infringing methods as a result of Mylan or Biocon marketing
`
`Yesafili using the proposed labeling we've just looked at?
`
`And so I want to get into the nitty-gritty of your
`
`answer in just a second, but let's answer that at a high level
`
`first.
`
`In your opinion, if Mylan or Biocon sell Yesafili
`
`with the proposed labeling we've just looked at, will doctors
`
`perform the method of Claim 6 and infringe Claim 6 as a result?
`
`A.
`
`Q.
`
`Yes.
`
`Okay. I want to talk a lot more about how and why
`
`you know that. Let's ask some prefatory questions first.
`
`Do ophthalmologists like yourself read labels?
`
`A.
`
`Q.
`
`A.
`
`Yes.
`
`Why?
`
`Well, there's several reasons. Especially when a
`
`drug comes onto the market, it gives us a good synopsis of the
`
`important information of that drug, right? It tends to be a
`
`synopsis of the data that supported its approval. So there
`
`typically is a recommended usage that we now can be understood
`
`C i n d y L . K n e c h t , R M R / C R R / C B C / C C P
`
`P O B o x 3 2 6 W h e e l i n g , W V 2 6 0 0 3 3 0 4 . 2 3 4 . 3 9 6 8
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2003 Page 322
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`
`
` 1
`
` 2
`
` 3
`
` 4
`
` 5
`
` 6
`
` 7
`
` 8
`
` 9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`KARL CSAKY, MD, PhD - DIRECT
`
` 332
`
`should be an approach that we should consider. It outlines
`
`again some of the issues, contraindications, reasons why you
`
`would not want to use it, what to look for.
`
`Other reasons -- for example, we have continuing
`
`medical education lectures, right? And those typically require
`
`that, if you're going to give a lecture on a drug, that you
`
`give it on-label, which means that, as you're talking about the
`
`aspects of the drug, that you're talking about it per the
`
`label. So that's typically either a requirement or that you
`
`have to notify the audience that you're going to be going
`
`off-label.
`
`And then of course in many cases sometimes insurance
`
`carriers, they utilize the label for reimbursement purposes,
`
`and so it's something you have to be aware of. So it's
`
`something that all of us from time to time will be either
`
`exposed to, read, or understand what's in the label.
`
`Q.
`
`Well, does what the label say influence the way that
`
`ophthalmologists use ophthalmic drugs?
`
`A.
`
`Q.
`
`A.
`
`Of course.
`
`Why?
`
`Well, because, again, I mean, we have to understand
`
`that there's several reasons that we'd want to look -- you
`
`know, as we look at a label, these are the guideposts, right?
`
`These are the instructions. And for many people, these are
`
`kind of a good way to start. They're going to say, okay,
`
`C i n d y L . K n e c h t , R M R / C R R / C B C / C C P
`
`P O B o x 3 2 6 W h e e l i n g , W V 2 6 0 0 3 3 0 4 . 2 3 4 . 3 9 6 8
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2003 Page 323
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`
`
` 1
`
` 2
`
` 3
`
` 4
`
` 5
`
` 6
`
` 7
`
` 8
`
` 9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`KARL CSAKY, MD, PhD - DIRECT
`
` 333
`
`here's how the agencies like the Food and Drug Administration,
`
`who has approved the drug, is -- has recommended that it be
`
`used. So, again, it gives us a starting point for how do we
`
`utilize the drug.
`
`So, again, there's lots of reasons to begin to review
`
`that, especially with a new drug as it comes out, that's
`
`something that we'll be exposed to and read.
`
`Q.
`
`So in view of that, Mylan or Biocon sells Yesafili
`
`with a label that recommends that doctors infringe Claim 6.
`
`Will some doctors actually do what that label says and use
`
`Yesafili according to the method of Claim 6?
`
`A.
`
`Q.
`
`Some doctors will in some patients.
`
`So I want to break things down a little bit because
`
`you're offering testimony about Yesafili, and I think we've
`
`established that drug's not on the market yet, right?
`
`A.
`
`Q.
`
`Yes.
`
`So how is it that you can form an opinion about how
`
`ophthalmologists will use Yesafili even though it hasn't been
`
`sold yet?
`
`A.
`
`Well, in forming my opinion I looked at how people
`
`use Eylea. And I reviewed the Eylea label and I asked myself
`
`is there any doctor with any patient that follows the label of
`
`Eylea in order to make my decision.
`
`Q.
`
`And if we bring back up PTX 917 on the left and
`
`PTX 3097 on the right, is there any difference between how
`
`C i n d y L . K n e c h t , R M R / C R R / C B C / C C P
`
`P O B o x 3 2 6 W h e e l i n g , W V 2 6 0 0 3 3 0 4 . 2 3 4 . 3 9 6 8
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2003 Page 324
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`
`
` 1
`
` 2
`
` 3
`
` 4
`
` 5
`
` 6
`
` 7
`
` 8
`
` 9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`KARL CSAKY, MD, PhD - DIRECT
`
` 334
`
`Regeneron recommends that doctors use Eylea and how Mylan or
`
`Biocon recommends that doctors use Yesafili?
`
`A.
`
`Q.
`
`Not that I can see.
`
`All right. In view of the fact that these labels
`
`make the same recommendations and in view of the fact that we
`
`just walked through your opinion that Mylan or Biocon's label
`
`encourages, recommends that doctors perform every method of
`
`claim -- excuse me -- every step of the method of Claim 6, does
`
`Eylea's label also recommend that doctors perform every step of
`
`the method of Claim 6?
`
`A.
`
`Q.
`
`Yes.
`
`Now, we touched on this at a high level before, but
`
`let's be a little more granular now. Do some doctors use Eylea
`
`in the way that Regeneron's label recommends?
`
`A.
`
`Q.
`
`A.
`
`Yes.
`
`How do you know?
`
`Well, in doing my assessment, I kind of reviewed
`
`several aspects. One, of course, is thinking back on how I
`
`have used Eylea. And, again, as I said, there are certain
`
`circumstances with certain patients, certain situations, where
`
`I have followed the label for lots of reasons.
`
`I've also -- when we sit on these committees and talk
`
`about various approaches, clearly there are lots of
`
`alternatives that people use, but there's still people who feel
`
`as if these label indications still in many cases they have
`
`C i n d y L . K n e c h t , R M R / C R R / C B C / C C P
`
`P O B o x 3 2 6 W h e e l i n g , W V 2 6 0 0 3 3 0 4 . 2 3 4 . 3 9 6 8
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2003 Page 325
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`
`
` 1
`
` 2
`
` 3
`
` 4
`
` 5
`
` 6
`
` 7
`
` 8
`
` 9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`KARL CSAKY, MD, PhD - DIRECT
`
` 335
`
`that comfort in knowing that this will give them good visual
`
`acuity in the patients that they want to treat.
`
`So I used several kind of indicators of trying to
`
`determine our -- again, are there some doctors in some patients
`
`who will utilize this approach? And the conclusion I came to
`
`was yes.
`
`Q.
`
`I want to take each of those reasons that you just
`
`offered in turn and dive in in a little more detail.
`
`You said you have used Eylea in the way the label
`
`recommends in accordance with the method of Claim 6. When and
`
`why?
`
`A.
`
`So, again, sometimes -- again, if you look -- I mean,
`
`the label basically suggests that, you know, I need to be
`
`giving three injections, which is again a very common approach
`
`for neovascular AMD. And then it instructs me to say, okay,
`
`wait eight weeks after that initial injection and do
`
`eight-weeks injections.
`
`And, again, there's certain circumstances, especially
`
`when there is -- I think back specifically to times when, for
`
`example, patients had challenges with scheduling, right? They
`
`want to know exactly kind of what to expect. They want to be
`
`able to figure out, Dr. Csaky, tell me exactly when I'm going
`
`to be coming in. I can give them some guideposts and metrics
`
`using this kind of approach.
`
`So there again, it's lots of reasons to have this
`
`C i n d y L . K n e c h t , R M R / C R R / C B C / C C P
`
`P O B o x 3 2 6 W h e e l i n g , W V 2 6 0 0 3 3 0 4 . 2 3 4 . 3 9 6 8
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2003 Page 326
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`
`
` 1
`
` 2
`
` 3
`
` 4
`
` 5
`
` 6
`
` 7
`
` 8
`
` 9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`KARL CSAKY, MD, PhD - DIRECT
`
` 336
`
`wider range of treatment options for patients as you talk with
`
`them and you ask them questions about what specifically --
`
`remember, this is a burdensome approach. And if somebody,
`
`especially in areas where they have trouble getting back and
`
`forth and they have to arrange certain trips, you know, having
`
`kind of a known schedule in certain circumstances can be really
`
`helpful for the patient. So, again, there have been some cases
`
`where I tried to and I have reviewed with the patient and I've
`
`used this approach.
`
`Q.
`
`A.
`
`Are there particular circumstances that stand out?
`
`Again, I think, you know, when I look back -- again,
`
`and this is typically in areas where getting to and from
`
`certain regions are challenging -- like, again, sometimes in
`
`these rural communities, it can be very challenging. If I'm
`
`there once a week and I don't have the luxury of being there
`
`often, it's nice to have that comfort to know the patients are
`
`coming back and forth.
`
`Also sometimes when I'm sharing a clinic with -- in
`
`this case in one of my satellite clinics, we can easily share
`
`patients because we kind of know what the schedules are going
`
`to be like. So, again, there's certain circumstances in which
`
`this type of approach can have some benefits.
`
`Q.
`
`And this type of approach, that's the fixed-dosing
`
`approach that's recommended by Eylea's label and covered by
`
`Claim 6?
`
`C i n d y L . K n e c h t , R M R / C R R / C B C / C C P
`
`P O B o x 3 2 6 W h e e l i n g , W V 2 6 0 0 3 3 0 4 . 2 3 4 . 3 9 6 8
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2003 Page 327
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`
`
` 1
`
` 2
`
` 3
`
` 4
`
` 5
`
` 6
`
` 7
`
` 8
`
` 9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`KARL CSAKY, MD, PhD - DIRECT
`
` 337
`
`A.
`
`Correct. So this is a -- an approach where, again,
`
`if you look at this label, it suggests that you want to have
`
`that patient come in once every month for three months and then
`
`start extending it to eight weeks.
`
`Q.
`
`Well, I understand that's your experience, Dr. Csaky.
`
`Is the retinal community such that you're familiar with how
`
`other doctors use Eylea?
`
`A.
`
`Yeah. I mean, I have -- like I said, I'm involved in
`
`lots of committees, discussions. Even with some of my fellow
`
`colleagues at Texas Retina, we talk about various approaches
`
`that people use. So, again, this is -- it's part of our
`
`armamentarium. What we want is we want to have different
`
`approaches in our armamentarium that we can offer patients and
`
`try to meet some of their needs and what they can have in terms
`
`of their scheduling and things like that.
`
`So that's really kind of a critical aspect to work
`
`with patients and fully appreciate what's the best for them in
`
`trying to get the best treatments.
`
`Q.
`
`And just to be very clear, in your conversations that
`
`you mentioned with other doctors, have you become aware as to
`
`whether other doctors used the fixed-dosage regimen recommended
`
`by Eylea's label and covered by Claim 6?
`
`A.
`
`Yeah, I've had certain -- like I said, discussions.
`
`And also I've seen certain documents where people have talked
`
`about using these kinds of approaches.
`
`C i n d y L . K n e c h t , R M R / C R R / C B C / C C P
`
`P O B o x 3 2 6 W h e e l i n g , W V 2 6 0 0 3 3 0 4 . 2 3 4 . 3 9 6 8
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2003 Page 328
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`
`
` 1
`
` 2
`
` 3
`
` 4
`
` 5
`
` 6
`
` 7
`
` 8
`
` 9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`KARL CSAKY, MD, PhD - DIRECT
`
` 338
`
`Q.
`
`Okay. During the course of preparing your opinion,
`
`did you come across a document reflecting how any particular
`
`doctor used the fixed-dosing approach?
`
`A.
`
`Yes.
`
`THE COURT: One second, Doctor.
`
`Yes, Counsel?
`
`MS. LESKO: Objection, Your Honor. I believe what --
`
`the document that counsel's about to refer to is the
`
`declaration of Dr. Do, who was an expert on behalf of Regeneron
`
`in a separate proceeding. That is hearsay. It should not be
`
`admissible. If they wanted to introduce Dr. Do as an expert in
`
`this case, they could have done it.
`
`THE COURT: Agreed, but, Counsel, go ahead.
`
`MS. KAYALI: Your Honor, we don't intend to seek
`
`admission of this document. Under Rule 703, Dr. Csaky is
`
`permitted to rely on such things. And he only intends to
`
`testify